Navigation Links
Hologic Announces First Quarter Fiscal 2008 Operating Results
Date:1/31/2008

g prices. The operating

loss for this business segment in the first quarter of fiscal 2008 was

$.6 million compared to operating income of $1.9 million in the first

quarter of fiscal 2007, reflecting an inventory impairment charge of

$2.0 million in the current quarter and a shift to more systems with

fewer features, lower selling prices and earning lower gross margins

which was offset in part by lower operating expenses. Skeletal Health

costs and expenses in the first quarters of fiscal 2008 and 2007

included $1.0 million and $.3 million, respectively, of stock-based

compensation.

Hologic's management will host a conference call today at 9:00 a.m. (Eastern) to discuss first quarter fiscal 2008 operating results. Interested participants may listen to the call by dialing 877-419-6600 or 719-325-48560 for international callers and referencing code 4664587 approximately 15 minutes prior to the call. For those unable to participate in the live broadcast, a replay will be available one hour after the call ends through February 5, 2008 at 888-203-1112 or 719-457-0820 for international callers, access code 4664587. The Company will also provide a live webcast of the call on the investor relations page of the Company's website at http://www.hologic.com/investor. A replay of the call will also be available on the investor relations page of the Company's website http://www.hologic.com/investor shortly after the completion of the live broadcast. A power point presentation related to the conference call will be posted in the investor relations page of the Company's website at http://www.hologic.com/investor.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium
'/>"/>

SOURCE Hologic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Hologic, Inc. to Release First Quarter Fiscal 2008 Operating Results Thursday, January 31st Before Market Opens
2. Hologic to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...rstCall/-YMBioSciencesInc.(NYSEAmex: YMI ;TSX:YM),...esandadvancesadiverseportfolioofpromisingcancer-re...ortedthatCytopia(ASX:CYT)hascommencedenrollmentofa...nisteredJAK1/JAK2inhibitor.Thetrialisbeingconducte...eCytopiaintoYMhasbeenpreviouslyannouncedandispendi...
(Date:11/23/2009)...xPharmaceuticals,Inc.announcedtodaythatithasappoin... Abramsbringsmorethan25yearsofdrugdiscoveryanddeve...learmedicineimagingagent,Cardiolite,andworkedfrom1...medicalResearchWorldwide.In1996,Abramsledtheestabl...rom1996to2006.AnorMEDdiscoveredanddevelopedMozobil...
(Date:11/20/2009)... , , , , , , , ... scientists from Washington University in St. Loui...aboratory and Iowa State University has finished s... Click here for more information. , , ..., , , , , , , , , I...
(Date:11/20/2009)...swire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX )...n public offering of 6,800,000 shares of its commo...e. The approximately $21 million of net proceeds,...mmissions, will be used for preclinical studies an...nal research and development programs, working cap...
Breaking Biology Technology:YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4Inimex Announces Appointment of New CEO 2Amaizing: Corn genome decoded 2Amaizing: Corn genome decoded 3Amaizing: Corn genome decoded 4Novavax Prices Public Offering of Common Stock 2
...ed at ASCO GI Symposia Continue to Support Picopla...in in First-Line Colorectal Cancer Treatment - , ...armaceuticals, Inc. (Nasdaq: PARD ), a biopharma...erapies, today announced updated efficacy and safe...inical trial of picoplatin in patients with metast...
...ensive tutorials on the publicly available PROSITE...searchers to quickly and effectively use these inv...tle (PRWEB) January 15, 2009 -- OpenHelix today ...on PROSITE, InterPro and IntAct, in addition to a ...database that can be used to browse and search for...
...s held in association,with the JP Morgan Healthcar...nc. (CTI) (Nasdaq and MTA: CTIC) reviewed 2009 tar...seeking to obtain two new drug approvals in 2009 i...n(R). In November CTI,established a 50/50 joint ve...m) for Zevalin. , "With a focus on cutting-edg...
Other Biology Technology:Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 2Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 3Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 4Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 5New and Updated Online Tutorials for PROSITE, InterPro, IntAct and UniProt 2New and Updated Online Tutorials for PROSITE, InterPro, IntAct and UniProt 3Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 2Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 3Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 4Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 5Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 6
(Date:11/23/2009)...strong evidence that the "synergistic" effect of e... pollution and indoor endotoxin causes more harm t...alone. , Environmental health scientists at th...e have shown that children exposed to both high le...oxin during early life are six times more likely t...
(Date:11/23/2009)...participants gathered this week for the seventh an...nference. This year,s topic, "Synthetic Biology," ...l researchers to explore the engineering, scientif...ld of synthetic biology. , Bonnie L. Bassler, pr...ty and this year,s conference chair, challenged th...
(Date:11/23/2009)...- A USDOE and USDA study concluded that 50 million...nd pasture could be converted from current uses to...chgrass, from which biomass could be harvested for...roduction of a perennial grass monoculture from wh...annually is expected to require nitrogen fertilize...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2Switchgrass produces biomass efficiently 2NAMI Launches New PSA Campaign 49413 1NAMI Launches New PSA Campaign 49413 2St Charles Surgical Hospital Announces Dedicated Lymphedema Treatment Program 49411 1St Charles Surgical Hospital Announces Dedicated Lymphedema Treatment Program 49411 2St Charles Surgical Hospital Announces Dedicated Lymphedema Treatment Program 49411 3Cox Movies Under the Moon 28R 29 Offers Big Screen Hits Under the Stars 49409 1Cox Movies Under the Moon 28R 29 Offers Big Screen Hits Under the Stars 49409 2Cox Movies Under the Moon 28R 29 Offers Big Screen Hits Under the Stars 49409 3
... not lower, costs and very large reductions in gre...d fuels. That,s one of the key take-home messages ...mass in America,s Energy Future (RBAEF)" in a spec...g . , The journal believes that the collection, ... a dozen mature technology biomass refining scenar...
... deepest point on Earth are dropping at an alarmi...ccording to Shahrazad Abu Ghazleh and colleagues f...many. The projected Dead Sea-Red Sea or Mediterran... carrying capacity to re-fill the Dead Sea to its ...ctricity and produce freshwater by desalinization....
...ch 3, 2009) Two new methods for analyzing the ro...e March issue of Cold Spring Harbor Protocols ( .... Wandless and colleagues from Stanford University...d instructions for "Regulating Protein Stability i...hnique provides a rapid, reversible, and tunable m...
Other Biology News:Cellulosic biofuel technology will generate low-cost green fuel, says major study 2Cellulosic biofuel technology will generate low-cost green fuel, says major study 3Is the Dead Sea dying? 2Protein function and chromatin structure methods featured in Cold Spring Harbor Protocols 2
...ansion Kit - Monolayer is a system designed for i...ree environment. The kit contains a specially form...ptimized for neural stem cell expansion (Johe, K.K...Human fibroblast growth factor basic (FGF basic) i...
DNA Polymerase I, E. coli from EPICENTRE Biotechnologies
...containing an overproducing clone of M-MLV Reverse...lyzes the polymerization of DNA using template DNA... large mRNAs, >10 kb, may be synthesized. M-MLV Re...ity than AMV Reverse Transcriptase resulting in hi...
...es the template-directed polymerization of nucleot...erase I possesses a 3?5 exonuclease activity or "p... during DNA replication, and also contains a 5?3 e...eplace nucleotides in the growing strand of DNA by...
Biology Products: